Zacks.com on MSN
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
Ranked by Local offices Pro Bono hours donated in 2024 Ranked by Taxes levied in 2024 Showcase your company news with guaranteed exposure both in print and online Join Charlotte Business Journal for ...
Together For Palestine's Lullaby enters Christmas Number 1 race ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback